cti-1601
Recombinant proteinexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2019 (NCT04176991)
Timeline
Indications
Studied for
Mechanism of action
- Frataxin, mitochondrialSupplementation
FXN supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095325 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06681766 | Phase 1 | Nov 30, 2024 | Larimar Therapeutics |
| NCT06447025 | Phase 2 | Jan 25, 2024 | Larimar Therapeutics |
| NCT05579691 | Phase 2 | Sep 21, 2022 | Clinilabs, Larimar Therapeutics |
| NCT04519567 | Phase 1 | Jul 31, 2020 | Clinilabs, Larimar Therapeutics, Metrum Research Group, LLC, Veristat, Inc. |
| NCT04176991 | Phase 1 | Nov 30, 2019 | Larimar Therapeutics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Larimar Therapeutics | For profit | 5 | 5 | 2 | 2019 |
| Clinilabs | For profit | 2 | 0 | 2 | 2020 |
| Metrum Research Group, LLC | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Veristat, Inc. | For profit | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1